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Hemagglutinin: a case of 
immunodominance of variable 
over conserved epitopes
The HA protein on the surface of influ-
enza viruses is by far the most important 
protein from the viewpoint of viral evolu-
tion and protective immunity. HA is com-
posed of a globular head that contains the 
receptor binding site, which is essential for 
viral attachment to receptors on host cells, 
and a stalk. A second surface protein, the 
enzyme neuraminidase (NA), promotes 
release of new flu viruses from infected 
cells. While antibodies that bind NA and 
other viral proteins and T cell–mediated 
immunity contribute to protection against 
influenza, only antibodies that recog-
nize the HA head are able to block viral 
binding and prevent entry into host cells 
(1, 2). These robust neutralizing antibod-
ies are the main effectors of the current 
inactivated (or killed) influenza vaccines 
and they are routinely quantified by HA- 
inhibition (HI) assay. Unfortunately, the 
head region is one of the most variable 
regions of the HA; therefore, vaccine 
strains need to be updated every few years 
to keep pace with the constant changes 
(also known as antigenic drift) in the HA of 
the circulating virus strains.
In 1982, it was shown that HI antibod-
ies mainly target five physically distinct 
antigenic sites in the HA head of H1N1 
influenza virus (3), which along with H3N2 
is currently circulating in humans. Not 
surprisingly, these antigenic sites are hot-
spots for amino acid mutations that lead to 
antigenic drift. Each antigenic site is typ-
ically formed by amino acids from differ-
ent loops of the HA and contains multiple 
epitopes (4). Moreover, these five antigenic 
sites are immunodominant compared with 
other antigenic regions in the HA head and 
stalk (ref. 4 and Figure 1). Antigenic sites in 
the stalk are much less variable and there-
fore are attractive targets for the develop-
ment of vaccines that offer broader protec-
tion (5). The weak point is that these sites 
are poorly immunogenic and thus evoke 
only weak antibody responses.
Rational vaccine design is further com-
plicated by the observation that the five 
individual antigenic sites also differ in their 
immunogenicity (4, 6). Research on this sub-
ject has been hindered due to the technical 
difficulty in mimicking the discontinuous 
and conformation-dependent B cell epitopes 
in the lab (4). The few available studies were 
mainly undertaken in mouse models with an 
H1N1 virus isolated in 1934. In this issue of 
the JCI, Liu et al. (7) determined the immu-
nodominance hierarchy of all five antigenic 
sites in the HA head of a contemporary H1N1 
strain (the 2009 pandemic virus) in humans 
and in three animal models.
Toward a rational selection of 
animal models for influenza
Liu and colleagues took an elegant and 
innovative approach to study the immuno-
dominance of each antigenic site in the 
HA head by creating a panel of five mutant 
viruses, each lacking a different antigenic 
site. This panel, along with the WT H1N1 
strain, was then used to evaluate site-specific 
HI antibody titers in sera from recently 
vaccinated humans and experimentally 
infected mice, guinea pigs, and ferrets, 
which are the three most commonly stud-
ied animal models for influenza research. 
These three species have somewhat differ-
ent immune responses to the virus and do 
not completely reflect human disease (8, 9). 
Mice, for example, are not natural hosts of 
influenza and may not accurately predict 
vaccine efficacy for humans (1). Ferrets 
are known for their very high and specific 
HI antibody titers, and sera from experi-
mentally infected animals are used as part 
of the strain selection process for the sea-
sonal human influenza vaccine. All species 
evaluated by Liu et al. mounted antibodies 
against the three antigenic sites nearest to 
the receptor binding site (referred to as Sa, 
Sb, and Ca2). However , there were some 
notable differences in the immunodom-
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The current inactivated influenza vaccines rely on the induction of 
neutralizing antibodies against the head domain of the viral hemagglutinin 
(HA). The HA head contains five immunodominant antigenic sites, all 
of which are subject to antigenic drift, thereby limiting vaccine efficacy. 
Bypassing the immune system’s tendency to focus on the most variable 
regions of the HA may be a step toward more broadly protective 
influenza vaccines. However, this requires a better understanding of the 
biological meaning of immunodominance, and of the hierarchy between 
different antigenic sites. In this issue of the JCI, Liu et al. determined 
the immunodominance of the five antigenic sites of the HA head in 
experimentally infected mice, guinea pigs, and ferrets. All three species 
exhibited different preferences for the five sites of the 2009 pandemic 
H1N1 strain. Moreover, human subjects exhibited yet a different pattern of 
immunodominance following immunization with the standard inactivated 
influenza vaccine. Together, these results have important implications for 
influenza vaccine design and interpretation of animal models.
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immunity, as well as genetic factors (4), 
likely contribute to the wide variations 
in HI profiles observed by Liu et al. How-
ever, the HI antibodies from most of the 
blood donors appeared to preferential-
ly bind the two most variable antigenic 
sites, Sa and Sb. Some donors that did 
not show an increase in total HI antibody 
titer after vaccination still exhibited sub-
tle changes in antigenic site immuno-
dominance. Liu and colleagues postulat-
ed that these changes may correlate with 
protection, as antibody function can vary 
tremendously between and even within 
antigenic sites (4).
One of the most important findings 
of Liu et al. is the detection of antibod-
ies against nonclassical, and presum-
ably less changeable, HA head epitopes. 
The authors designed a mosaic virus in 
which all five H1 antigenic sites were 
swapped out with the equivalent regions 
from an exotic H5 influenza virus. Anti-
bodies against this virus were rare in 
prevaccination samples but were read-
ily boosted by vaccination. This result 
is in accordance with several reports 
that infection or vaccination of adults 
with the 2009 pandemic H1N1 virus 
promotes generation of broadly neu-
tralizing antibodies (10–12). The anti-
tion. The different type and structure and 
supposedly broader neutralizing capaci-
ty of mucosal antibodies compared with 
those in the circulation warrant further 
studies of immunodominance in samples 
of the nose and lung.
The complex influenza immune 
repertoire in humans
Caution should be taken when using 
the findings of Liu et al. to compare 
responses in humans and experimental 
animals because of differences in the 
route and type of immunization and the 
immune history, all of which can alter 
immunodominance hierarchies (4, 6). 
The human subjects in this study were 
injected intramuscularly with the stan-
dard inactivated vaccine. Moreover, 
these subjects have encountered numer-
ous influenza virus infections and vac-
cinations with different H1N1 and other 
influenza viruses throughout their life-
time, and every subsequent exposure 
to a novel virus stimulates pre existing 
memory B cells to secrete antibodies to 
shared epitopes between old and new 
influenza strains. The exact exposure 
histories of the humans in the Liu et al. 
study are uncertain and differ between 
individuals. Differences in background 
inance of sites among species that may 
account for differences in the breadth of the 
antibody response. The HI antibodies from 
ferret sera preferentially bound the highly 
variable Sa site, a result that may explain 
the narrow specificity of HI antibodies from 
this species. In contrast, HI antibodies from 
guinea pigs did not favor one antigenic site 
over another, and this lack of antigenic 
site preference may be responsible for the 
exceptionally broad anti–HA antibody 
response of these animals (9).
A deeper understanding of these 
species-specific differences in antigenic 
site preference will definitely help to 
guide the choice of animal models used 
for future influenza vaccine studies. 
Especially as the outcome of a given study 
will largely depend on the model chosen. 
Moreover, antibody immunodominance 
is a complex phenomenon that is as 
dynamic as the immune response itself. 
The study by Liu et al. focused only on 
HI antibodies in the circulation, which 
have historically been used as a correlate 
of protection for inactivated flu vaccines. 
Unlike vaccination, infection with live 
influenza virus also locally induces anti–
HA antibodies in the respiratory tract and 
these mucosal antibodies are the prime 
mediators of protection following infec-
Figure 1. Schematic of influenza HA structure and variability. (A) Schematic representation of the structure of the H1N1 HA protein with its head and 
stalk domain. The HA head contains five immunodominant antigenic sites, designated Sa, Sb, Ca1, Ca2, and Cb. For the Sa and Sb sites, the S stands 
for strain-specific. These sites are most variable and are in close proximity to the receptor binding site. The C sites are cross-reactive sites that are less 
variable between H1N1 strains and are located further downward on the HA. (B) HA head epitopes that are outside the classical antigenic sites and, in 
particular, epitopes in the HA stalk are more conserved among different influenza A viruses. These sites are targeted to a much lower degree by anti-
body-producing B cells. (C) Influenza virus particle with HA and NA protruding from the surface. The combination of HA and NA proteins determines 
the subtype of the virus, such as H1N1, H5N1, etc.
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Why study 
immunodominance?
The 2009 H1N1 pandemic caused a surge 
of vaccination studies with sequential use 
of antigenically different influenza viruses 
and/or different types of vaccine. Many of 
these so-called heterologous prime-boost 
approaches aim at tipping the balance 
from immunodominant to subdominant 
epitopes. Additionally, there is now con-
sensus that an individual’s immune histo-
ry shapes the specificity of the antibody 
response to influenza and should be con-
sidered for future vaccine strategies (13, 
16, 17). Yet, it is poorly understood how 
immunodominance evolves over time 
and in response to exposure to different 
influenza virus strains. Mutant viruses, 
like those in the study by Liu et al., will 
help to address these knowledge gaps and, 
equally important, to compare the func-
tionality of antibodies against dominant 
versus less-dominant regions of the HA. 
Ultimately, such studies will empower the 
rational design of more broadly protective 
influenza vaccines.
Influenza A viruses infect many other 
species, including wild birds, poultry, 
horses, and pigs, in addition to humans. 
The pig is a neglected but valuable ani-
mal model for human influenza (18). In 
addition to the anatomy and physiology 
of the respiratory tract, the pathogen-
esis and immune response to influenza 
are similar in pigs and in humans. Pigs are 
naturally susceptible to the same influenza 
virus subtypes as humans, and similar vac-
cines are used in both species. Moreover, 
pigs were the source of the 2009 pandemic 
H1N1 virus and play an important role in 
the influenza virus ecology. Indeed, there 
is bidirectional virus transmission between 
pigs and humans, and pigs serve as a reser-
voir for older and more recent human virus 
strains (19). Due to their large size and lon-
ger life span, pigs are well-suited for the 
study of mucosal immune responses and 
the effects of sequential immunizations 
(20). Hopefully, the article by Liu and col-
leagues will stimulate future investigations 
with various influenza viruses in swine and 
other natural hosts.
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bodies described in these reports were 
capable of neutralizing a whole series 
of past human H1N1 drift variants that 
were substantially different from the 
novel pandemic virus. These antibodies 
were mainly directed against the con-
served HA stalk, but also targeted con-
served epitopes in the HA head (2). Both 
types of antibodies are hard to induce 
and are not commonly found. However, 
they can be induced by a strain in which 
most of the immunodominant epitopes 
are different from those in previously 
encountered viruses, such as the 2009 
pandemic virus. In this case, the rare 
memory B cells that react with subdom-
inant conserved epitopes seem to be 
able to expand and secrete antibodies 
(10, 11, 13). The HA stalk is much more 
conserved than the head, and it is the 
most promising target for a truly univer-
sal vaccine against any drift variants of 
human H1N1 and H3N2 viruses, as well 
as potentially pandemic bird flu viruses, 
such as H5N1, H7N9, and H9N2 (5). On 
the downside, anti–stalk antibodies can-
not prevent viral binding to receptors 
and only neutralize the virus after entry 
into the host cell, making these antibod-
ies less efficient. While antibodies to 
conserved HA head epitopes of a given 
H1N1 influenza strain will be ineffective 
against other subtypes, they would like-
ly offer more robust protection against 
H1N1 drift variants due to their vastly 
superior potency (2, 14). In other words, 
it is likely that the breadth of protection 
can only be maximized at the expense of 
potency. The results of Liu et al., there-
fore, call for further investigation of the 
functionality of the anti–mosaic virus 
antibodies and their target epitopes, 
which also appear attractive for vaccine 
design. Another highly relevant question 
is how adjuvanted vaccines would affect 
antibody levels to different HA head 
epitopes. The addition of an adjuvant to 
killed influenza vaccine is a simple but 
effective method to boost and broaden 
the immune response. The adjuvanted 
flu vaccine, which is licensed for popu-
lations over 65 years of age, contains the 
oil-in-water emulsion MF59. Interest-
ingly, MF59 has already been shown to 
stim ulate antibodies that react with a 
vastly increased number of epitopes in 
the HA head (15).
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